As attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has received a Letter of Authorization from Meril Healthcare Private Limited, an OEM of advanced orthopaedic and robotic systems, to act on its behalf for two projects related to Robotic Assisted Surgery Systems for Orthopedics. The projects are at the Directorate General Armed Forces Medical Services (DGAFMS) under the Ministry of Defence and INHS Asvini, a naval hospital in Colaba, Mumbai. Under this authorization dated October 8, 2025, Shukra can quote tenders, raise invoices, make supplies, submit offers, and collect payments for these projects. The authorization is valid till March 2026 or completion of the projects, whichever is earlier. The company says this marks its entry into the high-growth medical robotics and advanced orthopaedic healthcare segment. No order value, revenue impact, or contract value has been disclosed.
This is a positive strategic development as it opens Shukra Pharmaceuticals to the high-margin medical robotics and defence healthcare segment, potentially diversifying revenue. However, investors should note this is currently just an authorization to bid and supply — no confirmed orders, contract values, or revenue figures have been disclosed yet, so actual financial impact remains uncertain.